EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta‐analysis

Andreas Arnold-Vangsted, Marianne G Schou, Chandrakumar Balaratnasingam, Lasse J Cehofski, Jay Chhablani iD, Elon H C van Dijk, Nathalie S Eriksen, Jakob Grauslund iD, Javad N Hajari, M Cem Sabaner, Miklos Schneider iD, Yousif Subhi iD

Acta Ophthalmologica · 2025-05 · 103 (3) · 247-256

DOI: 10.1111/aos.16797 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Acta Ophthalmologica, online erschienen am 16.11.2024. Verfasst von Andreas Arnold-Vangsted und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Choroid, Choroidal Neovascularization, Polyps, Visual Acuity. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polypoidal choroidal vasculopathy (PCV) is an aneurismal type of macular neovascularization that show similarities with age‐related macular degeneration and diseases that are part of the pachychoroid disease spectrum. Exudative changes in PCV can be treated with intravitreal anti‐vascular endothelial growth factor monotherapy; however, a combination therapy with photodynamic therapy may be required. In this systematic review and meta‐analysis, we evaluated the efficacy of faricimab for PCV. We searched 12 literature databases for eligible studies. All study evaluation and data extraction were made by two authors in duplicate. Studies eligible for analysis were included for a qualitative and quantitative review. We identified seven studies with data from 150 eyes with PCV, five studies were of treatment‐naïve eyes who were commenced in faricimab monotherapy, and two studies were of switch‐over to faricimab from other anti‐VEGF drugs. After faricimab loading dose in treatment‐naïve eyes, the best‐corrected visual acuity (BCVA) remained stable at −0.09 (95% CI: −0.20–0.03) logMAR, central retinal thickness (CRT) decreased −169 (95% CI: −311–−27) μm, and 48.7 (95% CI: 32.5–65.0) % of eyes obtained polyp closure. In switch‐over eyes, 57%–67% experienced fluid reduction and 21% were able to extend their treatment interval. In conclusion, faricimab monotherapy for PCV leads to acceptable clinical outcomes in terms of stable BCVA, reduction of CRT, and high incidence of polyp closure. Some cases may benefit from a switch to faricimab. However, long‐term efficacy studies and controlled comparative studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChoroidChoroidal NeovascularizationPolypsVisual AcuityHumansAngiogenesis InhibitorsFluorescein AngiographyFundus OculiIntravitreal InjectionsPolypoidal Choroidal VasculopathyTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AAntibodies, Bispecific

Stichwörter der Autor:innen

anti‐VEGFefficacyfaricimabpolypoidal choroidal vasculopathysystematic review

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor AfaricimabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark.
  • Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
  • Lions Eye Institute, Perth, Western Australia, Australia.
  • Department of Ophthalmology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Western Australia, Australia.
  • Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Jay Chhablani, Jakob Grauslund, Miklos Schneider, Yousif Subhi

Zitieren

APA

Arnold-Vangsted, A., Schou, M. G., Balaratnasingam, C., Cehofski, L. J., Chhablani, J., van Dijk, E. H. C., Eriksen, N. S., Grauslund, J., Hajari, J. N., Sabaner, M. C., Schneider, M., & Subhi, Y. (2025). Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta‐analysis. Acta Ophthalmologica, 103(3), 247-256. https://doi.org/10.1111/aos.16797

Vancouver

Arnold-Vangsted A, Schou MG, Balaratnasingam C, Cehofski LJ, Chhablani J, van Dijk EHC, et al. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta‐analysis. Acta Ophthalmologica. 2025;103(3):247-256. doi:10.1111/aos.16797

BibTeX
@article{ArnoldVangsted2025,
  author = {Arnold-Vangsted, Andreas and Schou, Marianne G and Balaratnasingam, Chandrakumar and Cehofski, Lasse J and Chhablani, Jay and van Dijk, Elon H C and Eriksen, Nathalie S and Grauslund, Jakob and Hajari, Javad N and Sabaner, M Cem and Schneider, Miklos and Subhi, Yousif},
  title = {Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta‐analysis},
  journal = {Acta Ophthalmologica},
  year = {2025},
  volume = {103},
  number = {3},
  pages = {247--256},
  doi = {10.1111/aos.16797}
}
Kostenlos starten →